Form 4: Compass Therapeutics CEO Sells Shares for Tax Obligations
Insider Transaction Report
Compass Therapeutics CEO Thomas J. Schuetz reported the sale of 46,777 shares of common stock to cover tax withholding obligations related to RSU vesting.
Summary
- Thomas J. Schuetz, Chief Executive Officer and Director of Compass Therapeutics, Inc. (CMPX), reported a transaction on January 9, 2026.
- The transaction involved the disposition of 46,777 shares of common stock.
- The shares were disposed of at a price of $5.35 per share.
- This disposition was made to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
- Following this reported transaction, Mr. Schuetz beneficially owns 6,640,023 shares of common stock.
- The beneficially owned shares include unvested RSUs: 250,000 granted on February 8, 2023 (first installment vested February 8, 2024), 318,750 granted on January 9, 2024 (first installment vested January 9, 2025), and 250,000 granted on January 2, 2026 (first installment vests January 2, 2027).
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax obligations upon RSU vesting, which does not reflect a change in management's outlook or a strategic decision to sell. Therefore, the sentiment is neutral.
Industry Context
This filing is a routine insider transaction report (Form 4) common across all industries, particularly for executives receiving equity compensation. It does not provide specific insights into Compass Therapeutics' competitive position or broader industry trends.
Stakeholder Impact
- Shareholders: The transaction is a routine, non-discretionary sale for tax purposes and is unlikely to have a significant direct impact on shareholder value or perception. It reflects standard equity compensation practices.
- Employees: The RSU vesting and associated tax withholding are part of standard executive compensation, which may be viewed as a positive for employee retention and motivation through equity incentives.
Key Dates
| Date | Description |
|---|---|
| 02/08/2023 | Grant date for 250,000 restricted stock units (RSUs). |
| 01/09/2024 | Grant date for 318,750 restricted stock units (RSUs). |
| 02/08/2024 | First installment vesting date for 250,000 RSUs granted on February 8, 2023. |
| 01/09/2025 | First installment vesting date for 318,750 RSUs granted on January 9, 2024. |
| 01/02/2026 | Grant date for 250,000 restricted stock units (RSUs). |
| 01/09/2026 | Transaction date for the disposition of shares to cover tax withholding obligations. |
| 01/12/2026 | Signature date of the reporting person, Thomas J. Schuetz. |
| 01/02/2027 | First installment vesting date for 250,000 RSUs granted on January 2, 2026. |
Recommendation
holdThis Form 4 reports a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should continue to hold based on their existing analysis of Compass Therapeutics' fundamentals and future prospects.
Keywords
Compass Therapeutics, CMPX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, CEO Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.